Transaction DateRecipientSharesTypePriceValue
19th October 2020John Gordon Freund190,053Open or private sale$22.00$4,181,166.00
15th October 2020Shirley R. Kuhlmann7,060Open or private sale$20.82$146,989.20
30th September 2020Theodore R Schroeder1,211Payment by withholding$0.53$645.46
24th September 2020Rita J. Balice Gordon5,027Grant/award etc.$0.00
18th September 2020John Gordon Freund400,000Open or private sale$12.00$4,800,000.00
16th September 2020Shirley R. Kuhlmann734Payment by withholding$19.33$14,188.22
11th September 2020John Gordon Freund500,000Open or private sale$10.00$5,000,000.00
31st August 2020Theodore R Schroeder1,211Payment by withholding$0.62$750.09
19th August 2020John Gordon Freund500,000Open or private sale$8.72$4,360,000.00
11th August 2020Michael Thomas Heffernan13,071Open or private sale$19.13$250,048.23
Collegium Pharmaceutical
Collegium Pharmaceutical logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.


Collegium Pharmaceutical, Inc. operates as a pharmaceutical company. Its products include Xtampza ER, Nucynta ER and NucyNTa IR. The company was founded by Michael Thomas Heffernan in 2003.


Ticker: COLL
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1267565
Employees: 255
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $146 M (0%)
Inventory, Net: $19 M (0%)
Assets, Current: $251 M (-1%)
Property, Plant and Equipment, Net: $15 M (27%)
Other Assets, Noncurrent: $163 Th (-8%)
Assets: $647 M (111%)
Accounts Payable, Current: $8 M (30%)
Accrued Liabilities, Current: $25 M (0%)
Liabilities, Current: $252 M (24%)
Liabilities: $491 M (124%)
Common Stock, Value, Issued: $34 Th (0%)
Common Stock, Shares, Issued: $34 M (2%)
Retained Earnings (Accumulated Deficit): $351 M (-2%)
Stockholders' Equity (Parent): $156 M (0%)
Liabilities and Equity: $647 M (111%)
Revenue: $78 M (0%)
Cost of Revenue: $30 M (-55%)
Gross Margin: $48 M (-44%)
Research and Development: $2 M (-51%)
Operating Income/Loss: $17 M (-23%)
Provision for income taxes: $246 Th (0%)
EPS (basic): $0.23 (0%)
EPS (diluted): $0.23 (0%)